What question did this study set out to answer?

May 2, 2026

Trio of Phase I Studies Investigates Mesothelin-Directed CAR T-Cell Therapies.

Key Points

To evaluate novel mesothelin-targeted chimeric antigen receptor T-cell therapies for cancer treatment.
Three separate phase I studies conducted on distinct CAR T-cell therapies: SynKIR-110, UCMYM802, and M28z1XXPD1DNR.
Data presented at the American Association for Cancer Research Annual Meeting.
Findings from the studies demonstrate initial safety and efficacy for each mesothelin-targeted therapy.
Specific outcome metrics and detailed results were not provided in the abstract.

Abstract

At the American Association for Cancer Research Annual Meeting, researchers presented data from three separate phase I studies investigating distinct mesothelin-targeted chimeric antigen receptor T-cell therapies: SynKIR-110, UCMYM802, and M28z1XXPD1DNR.

Mark Helpful

Bookmark

Relay

Cite This Study

A Thu, study studied this question.

synapsesocial.com/papers/69f5943c71405d493afff121 https://doi.org/https://doi.org/10.1158/2159-8290.cd-nw2026-0049

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Mark Helpful

Bookmark

Relay